GlassScriptPhysician profile
Angela Falco
NPI 1760471841
$3,482.49
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,368 · 2022: $288 · 2023: $571 · 2024: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.89 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,653.47 | 2021-2022 | |
| Celgene Corporation | $512.44 | 2021 | |
| Abbvie INC. | $498.52 | 2021-2024 | |
| Beigene USA, INC. | $184.57 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $165.33 | 2022-2023 | Darzalex, Carvykti, Tecvayli |
| Gilead Sciences, INC. | $125.00 | 2023 | |
| Seagen INC. | $99.00 | 2021 | |
| Kyowa Kirin, INC. | $93.59 | 2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $74.59 | 2022-2024 | |
| Incyte Corporation | $44.74 | 2024 | Jakafi |
| Astellas Pharma US INC | $31.24 | 2023 | Xospata |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Falco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.